Medicare Coverage for Blood Tests to Screen Early Alzheimer's and Dementia.
This Act amends the Social Security Act to mandate Medicare coverage for blood-based screening tests designed for the early detection of Alzheimer's disease and related dementias. This change ensures that citizens covered by Medicare will have access to advanced testing for pre-symptomatic or early-stage detection, facilitating timely intervention. The new coverage provisions are scheduled to take effect starting January 1, 2028.
Key points
Medicare Expansion: Medicare coverage will be extended to include early detection screening tests for Alzheimer's disease and related dementias.
Early Detection Focus: The tests covered are specifically for detecting the pre-symptomatic and early stages of the disease, crucial for potential treatment effectiveness.
Covered Tests: Coverage includes genomic sequencing blood tests and other FDA-approved equivalent tests, such as protein analysis and medical imaging based on biospecimens.
Effective Date: These new benefits will become available to Medicare beneficiaries starting on January 1, 2028.
Introduced
Citizen Poll